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Abstract: The diagnostic phenotype of nonalcoholic fatty liver disease (NAFLD)—in particular, the
most significant form in terms of prognosis, nonalcoholic steatohepatitis (NASH)—continues to rely
on liver tissue evaluation, in spite of remarkable advances in non-invasive algorithms developed from
serum-based tests and imaging-based or sonographically-based tests for fibrosis or liver stiffness.
The most common tissue evaluation remains percutaneous liver biopsy; considerations given to the
needle size and the location of the biopsy have the potential to yield the most representative tissue
for evaluation. The pathologist’s efforts are directed to not only global diagnosis, but also assessment
of severity of injury. Just as in other forms of chronic liver disease, these assessments can be divided
into necroinflammatory activity, and fibrosis with parenchymal remodeling, in order to separately
analyze potentially reversible (grade) and non-reversible (stage) lesions. These concepts formed the
bases for current methods of evaluating the lesions that collectively comprise the phenotypic spectra
of NAFLD. Four extant methods have specific applications; there are pros and cons to each, and this
forms the basis of the review.
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1. Introduction
The value of liver biopsy evaluation for diagnosis in clinical care and effectiveness of intervention
in clinical research in the field of nonalcoholic fatty liver disease (NAFLD) has remained unquestioned
as knowledge in the field has continued to grow over the course of the last three and a half decades
since the publication attributed as one of the early descriptions in humans [1]. Currently several clinical
algorithms based on serum-based tests can be used to predict the likelihood of NAFLD, nonalcoholic
steatohepatitis (NASH) or presence or severity of fibrosis, reviewed [2]. As well, sonographically-based
tests of liver “stiffness” and imaging-based tests for presence of hepatic fat are variably validated
and becoming more available [3]. The unquestioned value of all non-invasive testing is for patient
follow-up; in sophisticated hands, these tests also play a role in determination of need for liver biopsy,
as the latter, an invasive test with known low but potential risk of morbidity cannot be utilized
as a screening test [4]. The best noninvasive tests have been developed and validated against the
“gold-standard” of liver biopsy in order to produce equivalent information regarding the state of the
liver parenchyma.
Liver biopsy cannot be considered a “perfect” test, however, but the short-comings of this can
largely be overcome once understood. For instance, the consideration of sampling “error” [5] was
detailed in a study in 2005 that demonstrated differences in grade and stage by the blinded pathologist
even when biopsies were obtained from the identical location. However, as in most chronic liver
diseases, this “error” is likely a reflection of the disease heterogeneity of NAFLD, and must be
accounted for by providing sufficient numbers of subjects in clinical trials. Another less well-known
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short-coming of liver biopsy, particularly when done by radiologists, or in the setting of bariatric
surgery, is the use of appropriately sized (i.e., large-bore) needles, [6], and potential differences between
the right and left lobes of the liver. For instance, the subcapsular portal tracts in the left lobe are larger
and closer to the capsule than in the right lobe; if not aware of this, a pathologist can misinterpret the
seemingly enlarged portal structures from a left lobe biopsy for fibrotic portal structures, particularly
if a small bore needle has been used to obtain the biopsy. Determining histologic inflammation in
the liver parenchyma will not lead to valid results from a biopsy obtained in a surgical procedure,
as anesthesia alone will lead to parenchymal and perivenular collections of polymorphonuclear
leukocytes, collectively known as “surgical hepatitis”. Discerning which foci were present prior to
anesthesia, and which are due to surgical hepatitis is not possible. Further, if a study protocol includes
biopsy, agreement of exact location should be made in advance with all investigators so that pre and
post intervention biopsies are truly comparable. Finally, the interpreting pathologist’s expertise and
familiarity with the spectra of lesions in the disease process are factors to be considered in NAFLD, as
in any other form of liver disease [7,8].
Once the decision for liver biopsy has been made, whether for clinical (i.e., diagnostic or
prognostic) purposes, or for clinical trial protocol, the next steps involve the histopathologic
interpretation for diagnosis, and for semi-quantitative lesion evaluations, if requested, for protocol or
study purposes. Methods for these are the subjects of the remainder of this review.
2. Diagnosing Fatty Liver Disease in Liver Biopsy
Before any form of assessment of severity of injury or fibrosis can be applied, the pathologist must
be certain that the biopsy actually is diagnostic of the clinically presumptive disease; this basic exercise
applies to all forms of liver disease. NAFLD is an umbrella term applied to a range of histopathologic
phenotypes in adults, adolescents and children. It is important that the pathologist report is limited to
the findings noted, and count on the clinical team to put these together with all information regarding
possible etiologies that may present in a similar manner, including, for instance, Wilson disease, other
inborn errors of metabolism, and alcoholic liver disease. Discussed in detail in recent reviews [9], they
will be briefly summarized herein. In adults, prior to advanced fibrosis and parenchymal remodeling
(nodularity), the parenchyma shows varying degrees of steatosis within the zone 3 hepatocytes (those
around the terminal hepatic venule). The large and small droplet steatosis is termed macrovesicular
due to the fact it is either a single large droplet or several droplets readily separable to the microscopic
eye. Often, the two are co-existent in the same hepatocyte. Thus, the term, “large and small droplet
macrovesicular steatosis” is applied. When only steatosis is present in the biopsy, the diagnostic term,
NAFL, is given. For this, >5% of hepatocytes within the biopsy must be occupied by this type of visible
fat droplets. In a minority of cases, non-zonal clusters of hepatocytes also have true microvesicular
steatosis; an association was noted with greater severity of disease in these cases in a large series
from the NASH Clinical Research Network (CRN) [10]. The terminal “D” of NAFLD is removed
by convention, as steatosis is considered non-progressive, although exceptions have been noted in
subjects, most of whom subsequently gain weight or the metabolic status changed [11,12].
The second component of NAFLD is inflammatory cells; these may be seen within the acini
(aka lobules), or in portal tracts, or both. The inflammatory components of this disease are quite
complex, but with the routine hematoxylin and eosin stain to the pathologist’s view microscopically,
can be divided into mononuclear cells (lymphocytes, monocytes), eosinophils, polymorphonuclear
cells (pmn’s), and Kupffer cells. Even occasional plasma cells can be noted. Kupffer cells are pigmented,
enlarged and either singly or in clusters surrounding an apoptotic hepatocyte (microgranuloma) or a
fat droplet (lipogranuloma). Lipogranulomas often have an associated eosinophilic leukocyte, and
when adjacent to a terminal hepatic venule or within a portal tract, may also have collagen. Epithelioid
or caseating granulomatous inflammation are not features of NAFLD, and deserve further attention.
Pmn’s surrounding individual hepatocytes, referred to as “satellitosis”, are indicative of alcoholic
hepatitis; clusters of pmn’s signify possible sepsis or may occur if the biopsy is obtained during a
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surgical procedure when the patient is under anesthesia. Thus, caution is warranted when pmn
clusters are easily noted; attempting to “count” inflammatory foci in such a specimen is not advisable.
Portal inflammation consists of similar cell types as described above (except the macrophages are
not Kupffer cells) in varying degrees, including lipogranulomas. Other types of granulomatous
inflammation should be further evaluated. Bile duct injury may be seen, but should be
further evaluated. Marked portal inflammation and lymphoid aggregates, diffuse interface
activity, and plasma-cell rich infiltrates are all lesions that deserve further investigation.
Numerous polymorphonuclear leukocytes, when present, are typically present as cholangitis,
cholangiolitis/pericholangitis and indicate an extra-hepatic biliary process such as obstruction or
pancreatitis, or alcoholic liver disease. Canalicular bile plugs in zone 3 correlate with these findings
and warrant further investigation. Cholangiolar bile is indicative of sepsis. The combination of
macrovesicular steatosis and inflammation has been termed steatosis with inflammation; this is not,
however, diagnostic of steatohepatitis.
2.1. Nonalcoholic Steatohepatitis (NASH)
For the diagnosis of NASH, the most recognized form of injury in NAFLD with potential to
progress to fibrosis and cirrhosis and its complications, there is a requirement not only for the
steatosis and inflammation as described above, but also for a particular form of hepatocyte injury
known as ballooning. While some authorities have stated that steatosis with inflammation and
perisinusoidal fibrosis are adequate for a diagnosis of steatohepatitis, it is not clear that this group
of findings represents a lesion with actual potential of progression, or represents a step in regression
of steatohepatitis (i.e., loss of ballooning). The NASH CRN Pathology Committee categorizes this
within a set of lesions as “Borderline, Zone 3”, and specifies that hepatocellular ballooning must be
present for a diagnosis of steatohepatitis. NASH can be diagnosed in the absence of fibrosis. The initial
collagen deposition in adult NASH is in the perisinusoidal spaces in zone 3; with progression, fibrosis
is additionally noted in periportal spaces, often associated with a ductular reaction. More advanced
fibrosis is indicated by bridging between vascular structures: central veins to central veins (via
perisinusoidal spaces); central–portal; portal–portal; with nodularity of the intervening parenchyma.
Cirrhosis is the final outcome of advanced fibrosis and remodeling. Residual perisinusoidal fibrosis
may or may not remain.
An intriguing and important concept in NASH is that with advanced disease, i.e., fibrosis and
architectural remodeling with bridging fibrosis and nodularity, and ultimately the vascular remodeling
of cirrhosis, the lesions of activity described above may or may not continue to be present. Investigators
have used this information to justify a correlation with the assignment of the diagnosis of “cryptogenic
cirrhosis” to cases in which no identifying lesions of active liver disease can be found. In a strict sense,
however, without a prior biopsy diagnosis of NASH, this may not be correct in all cases. Many cases
of cryptogenic cirrhosis, in fact, may be burned-out cirrhosis from other causes such as prior alcohol
abuse, autoimmune hepatitis, heterozygous α-1-antitrypsin liver disease, or even more rare processes
(e.g., keratin mutations). However, there are bona fide cases of burned-out NASH in which there
remain histologic “hints”: e.g., foci of perisinusoidal fibrosis, occasional ballooned hepatocytes, rare
Mallory–Denk bodies in a non-alcohol user. If there is a prior biopsy with NASH, the “burned-out”
cirrhosis is no longer “cryptogenic”, but is cirrhosis secondary to prior NASH.
2.2. Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
Pediatric NAFLD is known to be unique in its pre-cirrhotic histopathologic features. This has been
accepted since the seminal descriptions of Schwimmer et al. in 2005 [13], and validated subsequently by
others. Interestingly, as of yet, there is no accepted diagnosis of “steatohepatitis” in children, although
clearly the end results, cirrhosis and hepatocellular carcinoma, do occur. The initial findings in children
are of large droplet macrovesicular steatosis either in a periportal or panacinar distribution and when
inflammation is present, it is more common in the portal collagen than in the lobules. Ballooned
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hepatocytes are few if any. Portal expansion by fibrosis occurs initially, and perisinusoidal fibrosis may
or may never be seen. The categorization of Borderline, Zone 1 has been utilized by the NASH CRN
for the above-described lesions.
3. Grading and Staging the Lesions of NAFLD
Four current methods of semi-quantitatively evaluating histologic lesions of NAFLD are
summarized in Table 1; they include a proposal referred to as the “Brunt” system [14], the NASH CRN
Pathology Committee system for NAFLD Activity Score (NAS) and fibrosis score [15], the “Fatty Liver
Inhibition of Progression (FLIP)” algorithm [16,17] and a pediatric score based on weighted values for
the features of NAFLD, the Pediatric NAFLD Histologic Score [18]. The first was restricted to adults
and to NASH; the middle two can apply to the full range of NAFLD; the NASH CRN system alone
applies to adults and children.
3.1. Brunt Proposal for Grading and Staging
The proposal for grading and staging the lesions of NASH was made when the disease itself was
still being questioned as an entity other than surreptitious alcoholism; it was clear that further work
would not progress until a systematic method of analyzing the pathology was in place. Thus, this
proposal was just that: a first proposed method to separately analyze grade and stage, similarly to
what was being done with other forms of chronic hepatitis, but with adjustments for the lesions of
fatty liver disease [14]. There was systematic review of 52 adult biopsies from 51 clinically diagnosed
subjects with NASH with semi-quantitative assessment and notation of location of steatosis, and
ballooning; semi-quantitative assessment for lobular and portal inflammation and Periodic Acid
Schiff after diastase digestion (PASd) Kupffer cells, Mallory–Denk bodies, acidophil bodies, iron, and
glycogenated nuclei, lipogranulomas and locations of fibrosis, zone 3 perisinusoidal, portal/periportal,
and bridging. “Gestalt” diagnosis of severity of each case (mild, moderate, severe) then followed. The
“global grade” was based on review of the semi-quantitative lesions and impression-based grades,
and focused in particular on steatosis, hepatocellular ballooning, zone 3 accentuation of injury. It
was noted that the initial, and often persistent form of fibrosis is perisinusoidal; this differs from the
distinctly portal-based fibrosis of chronic hepatitis and biliary fibrosis. The so-called “Brunt” method
continued the paradigm of maintaining separation of grade (lesions of activity) and stage (lesions
of fibrosis and parenchymal remodeling), as had been established by the systems for evaluation in
chronic hepatitis [19]. The method of grading and staging was written to be applied after the diagnosis
of NASH had been rendered, and was considered a “global” assessment such that grades 1–3, mild,
moderate and severe, were evaluations of combinations of steatosis, lobular and portal inflammation
and ballooning. Hepatocyte ballooning was noted as the major determinant of severity and steatosis
amount was the least determinant; inflammation increased with each grade. Fibrosis was scored
according to the observed location and extent of collagen deposition as described above. Grade and
stage were noted to be disparate, as in chronic hepatitis although none of the low stage biopsies showed
severe steatohepatitis. Higher grade did correlate with higher mean aspartate aminotransferase (AST),
but not with alanine aminotransferase (ALT). This system was created for NASH, and thus did
not take into account the full spectrum of NAFLD, nor did the system address lesions of pediatric
NAFLD. Although the system has been widely utilized and applied, it was never formally validated.
It is, however, a useful benchmark for diagnosing NASH as it highlighted the increasing severity of
ballooning with increased severity of grade. This proposal also documented the characteristic fibrosis
of adult NASH.
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Table 1. Histologic methods of semi-quantitative evaluation of nonalcoholic fatty liver disease (NAFLD).
System/
Characteristics Brunt System [14] NASH CRN [15] * SAF/** FLIP Algorithm [16,17] Pediatric NAFLD Histologic Score [18]
Patient Population Adults only Adults + Children Adults Children
Applicable to NASH All NAFLD All NAFLD Peds NAFLD
Grade
Mild, Moderate, Severe;
S + LI, PI + B;
Unweighted but steatosis does not
affect score; LI + PI, ballooning
increase incrementally with score
NAFLD Activity Score (NAS):
S + LI + B = 0–8;
Unweighted scores for each lesion
Steatosis is not a component of activity Activity:
LI + B;
* SAF: Steatosis + Actitivity + Fibrosis = SxAxFx;
** FLIP: Fatty Liver Inhibition of Progression
algorithm for diagnosis
Weighted sums of S + LI + PI + B, see text
Details of Scoring
Steatosis Steatosis Steatosis
Same as NASH CRN plus Portal
Inflammation 0–2
0: 0 0: <5% 0: <5%
1: 0%–33% 1: 5%–33% 1: 5%–33%
2: 34%–66% 2: 34%–66% 2: 34%–66%
3: >66% 3: >67% 3: >67%
LI LI LI
0:0 0:0 0: 0
1: 1–2/20x 1: <2/20x 1: <2/20x
2: 2–4/20X 2: 2–4/20X 2: 2/20x
3: >4/20X 3: >4/20X –
PI: Ballooning: Ballooning: 0–2
0: none 0: None 0: 0
1: mild 1: Few 1: clusters, reticulated cytoplasm
2: moderate 2: Many 2: enlarged hepatocytes
3: severe – –
Ballooning Prominent –
Acinar location – –
Mild – –
Marked – –
Fibrosis Stage Fibrosis Stage Fibrosis Stage
Fibrosis Stage: As with NASH CRN
0: none 0: none F0: 0
1: zone 3 perisinusoidal
1a: zone 3 perisinusoidal, delicate
F1: zone 3 perisinusoidal (all), or portal only1b: zone 3 perisinusoidal, dense
1c: portal only
2: 1 + periportal 2: 1a or 1b + periportal F2: zone 3 + periportal
3: bridging 3: bridging F3: bridging
4: cirrhosis 4: cirrhosis F4: cirrhosis
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Table 1. Cont.
System/
Characteristics Brunt System [14] NASH CRN [15] * SAF/** FLIP Algorithm [16,17] Pediatric NAFLD Histologic Score [18]
Fibrosis Stages 0–4 0–4; # 1a, 1b, 1c 0–4; # 1a, 1b, 1c 0–4
Scoring Method Used for diagnosis Minimal criteria for dx
Correlates but does not replace;
used in clinical trials for
feature comparisons
Yes, for diagnosis Yes, for diagnosis
Clinical Associations Grade: AST ALT, AST AST, ALT WC, MetSynd, TG, Fibrosis in biopsy
S = steatosis amount; LI = lobular inflammation; PI = portal inflammation; B = ballooning; # 1a, 1b, 1c: see text. ALT = alanine aminotransferase; AST = aspartate aminotransferase;
WC = Waist circumference; MetSynd = Metabolic Syndrome; TG = triglyceride levels.
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3.2. NASH Clinical Research Network (CRN) Scoring System
The National Institute of Digestive Diseases and Kidney (NIDDK) of the National Institutes
of Health (NIH) established the NASH Clinical Research Network (CRN) in order to undertake
multicenter observational and interventional trials. The Pathology Committee was tasked with
developing and validating a method for semi-quantitatively evaluating changes in histologic features
in these studies. The result was a feature-based system referred to commonly as the NAFLD Activity
Score (NAS) [15]. This is a score for lesions of activity based on carefully analyzed results of
32 twice-reviewed biopsies of adults and 18 once reviewed biopsies of children by a group of 9 liver
pathologists. The review consisted of 14 lesions of NAFLD (the same as above in similar fashion,
plus presence of foci of microvesicular steatosis, megamitochondria, and microgranulomas) and three
diagnostic categories: NASH, not NASH and borderline. The lesions that ultimately comprised the
NAS were determined by multiple logistic regression to correspond with the separately derived
diagnoses of NASH: macrovesicular steatosis, lobular inflammation and ballooning. The final NAS
was based on unweighted scores of each, and ranged from 0 to 8. As noted in Table 1, although
the lesion scores are unweighted, the fact that steatosis and lobular inflammation range from 0 to 3
whereas ballooning range from 0 to 2, gives steatosis more weight in the NAS. The separately derived
diagnoses of NASH mostly correlated with scores ě5; NAS < 3 had been diagnosed as not NASH.
Fibrosis stage was a modification of the Brunt system in order to account for pediatric portal-only
fibrosis (stage 1c); zone 3 delicate (1a) or dense (1b) fibrosis were created for the purpose of clinical
trials. The manuscript that presented the NAS described other observations of importance that remain
relevant today: the diagnosis does not rest solely on the presence of particular lesions; the score was not
created to replace a pathologist’s diagnosis or as a severity scale or to measure rapidity of progression,
but rather as a method of analysis in assessing overall histologic change. A subsequent study of 976
centrally reviewed adult biopsies from the NASH CRN highlighted the significance of separating the
pattern-based pathologists’ activity of diagnosis from the feature-based score [20]. Although there was
significant overlap between the diagnosis and the NAS, some details are worth re-iterating. While
75% of definite steatohepatitis cases had NAS ě 5, 28% of borderline diagnoses and 7% of “not NASH”
also had NAS ě 5. Thus, for clinical trial entry, or for clinical management, if the NAS were the
basis of decision making, the latter and last cases would be “mis-categorized”. Further, and of most
importance, in a regression model, while both the diagnosis of steatohepatitis and the NAS were
statistically strongly associated with liver enzymes (ALT and AST) in both the one variable (either
NAS or NASH diagnosis) and two variable (both NAS and NASH diagnosis) models, and features of
Metabolic Syndrome, diabetes, and measures of insulin resistance, the homeostatic model assessment
of insulin resistance and the quantitative insulin sensitivity check index (HOMA-IR and QUICKI)
were associated with both in the one variable model, these latter features only remained statistically
associated with the diagnosis of steatohepatitis in the two variable model. Thus, the implication is
strong that not only are the particular histologic features of steatohepatitis important, but the overall
pattern of those features (i.e., the determination of diagnosis) is important in correlation with liver
injury, as well as underlying factors of the disease process.
3.3. Fatty Liver Inhibition of Progression (FLIP) Algorithm
A third approach to adult NAFLD scoring has been proposed and validated by Bedossa et al. [17];
the score was developed in 679 liver biopsies from morbidly obese patients undergoing bariatric
surgery with at least one metabolic complication (i.e., diabetes, hypertension, dyslipidemia or
obstructive sleep apnea), and validated in 60 liver biopsies of subjects with metabolic syndrome,
but not morbid obesity. The algorithm, subsequently tested for observer variability by two groups of
pathologists, a European study group, the Fatty Liver Inhibition of Progression (FLIP) pathology group,
and a pathology group of general pathologists with varying amounts of liver pathology training [16].
The score is based on two now recognized concepts; even though large droplet macrovesicular steatosis
is an obviously recognized, and required, feature of non-cirrhotic NAFLD, it is likely not a driver in
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progression of disease, thus, the feature should not carry much weight, if any at all, in a histologic
score. However, ballooning and lobular inflammation have been noted in several studies to be
significant features in progressive disease, thus, these should be more weighted as determinants of
progression. Thus, the “activity score” is derived from the combination of the semi-quantitative values
of the two [17]. The details for semi-quantitative scores differ slightly from prior methods: lobular
inflammation ranges from 0 to 2 (instead of 0–3), ballooning 0–2 (with descriptions of ballooning
as detailed in Table 1). As the final score is meant to represent a diagnosis, steatosis (Sx) must be
>0, activity (ballooning plus lobular inflammation (Ax) must be ě2, in which ballooning is at least 1.
Fibrosis is based on the NASH CRN scale, and reported as “F”. One of the primary advantages of
this score is the manner of reporting: by giving a subscore for each component of the SAF (Steatosis
+ Activity + Fibrosis), the amount of steatosis and fibrosis are communicated and one may make
comparisons for the features with other biopsies from the same patient. Activity, the most important of
the scores is an additive score, so, similar to the NAS, one cannot determine how much is ballooning
and how much is lobular inflammation, thus, as with the NAS, improvement in either would not
be visible by the SAF alone. Increased values of the SAF correlated well with increased values of
serum AST and ALT. Correlations with known metabolic features of NAFLD/NASH, such as markers
of insulin resistance, were not reported for the different activity scores that discriminate NAFLD
and NASH.
The second study done by the FLIP pathologists and a group of community pathologists [16] was
done to test the validity of the SAF algorithm in non-bariatric subjects as well as to test the usefulness
of such an algorithm for practical use. Both groups of pathologists’ diagnoses improved when the SAF
was utilized and both groups had high kappa values when utilizing the SAF. One of the discussed
concepts was the challenge for pathologists to make the distinction(s) of NASH and non-NASH in liver
biopsy material, whereas use of an algorithm such as the SAF could mitigate against the necessity of
such. An example given was a case of steatosis with only fibrosis, but no other features. Additionally,
the graphic of the SAF score showed that it could be possible to have S > 0 A1(B1 + L0) (i.e., steatosis
> 0, activity score of 1 because of ballooning score of 1 but no lobular inflammation) with a final
diagnosis of “steatosis”. Both of these examples are troublesome and highlight the oversimplification
of the SAF on its own. The former could potentially fit into a “borderline” category of either zone 1 or
zone 3 depending on where the fibrosis is located and the latter could fit into borderline zone 3, also
depending if the ballooning and steatosis were in zone 3. Alternatively, both could fit into examples
of resolution of prior NASH, and one would want to compare them with prior biopsies. Although
both of the studies that proposed and discussed the values of the SAF reiterated that it was not meant
to replace a written pathology report, neither mentioned the authors’ concepts of fundamentals of
NASH diagnosis other than the presence of the lesions in the SAF. Zonal localization and accentuation
of lesions in adults and children were not assessed, nor can they be, by the algorithm proposed.
3.4. Pediatric NAFLD Histologic Score
The final scoring system proposed is specifically for the pediatric group by Alkhouri et al. [18].
The score proposed was developed from 203 biopsies of children with NASH or “notNASH” according
to the pathologist’s diagnosis, and given NAS and fibrosis scores according to the NIDDK NASH CRN
system with the exception of adding a portal inflammation score of 0–2 for none, mild or moderate
portal inflammation. After logistic regression, each feature was weighted and a final Pediatric NAFLD
Histologic Score (PNHS) was developed that can be calculated by entering their values into the
website [21]. Both the training and validation sets had high area under receiver operating curve
(AUROC) values. Interestingly, 65.9% of NASH biopsies had ballooning, as did 4.4% of notNASH
biopsies, but 34.1% of NASH biopsies also were diagnosed as such without ballooning. The NAS was
greater in NASH biopsies than in notNASH biopsies (mean values 4.5 ˘ 1.4 vs. 2.2 ˘ 0.59, p < 0.001),
as expected, as was fibrosis >0 (p < 0.001). The score was developed in order to better reflect pediatric
“NASH” than the term “borderline” steatohepatitis for both clinical care and clinical trials. Whether
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it has been in use long enough to accomplish this goal or not cannot be clearly stated at this time.
The need to utilize a website for determination of a score and therefore a diagnostic category is
interesting and the goal worthwhile, but the concept is somewhat worrisome to diagnostic pathologists
as the suggestion that a calculated algorithm can actually replace the interpretative experience that
is involved in deriving a final diagnosis is not something one accepts with certainty. The “art” of
interpretation continues to play a role in all fields of medicine, regardless of the rigor with which it
is applied.
4. Conclusions
It is apparent that NAFLD and NASH are complex entities, not only for clinicians, basic scientists,
but also for diagnostic pathologists. Even though much progress has been made, it is worthwhile to
remember that scoring methods are measures of injury, but not replacements of diagnostic assessment,
and thus, pathologists need to first be trained to recognize patterns of disease, and then to apply
appropriate scoring systems. There are pros and cons to any scoring system for all disease processes,
as discussed above for NAFLD and NASH. As continued work is done, however, the expectations for
more “pros” and fewers “cons” remain.
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